Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

GPRO, HIRU Medical Market News Report from CRWEFinance.com

|Includes: Hologic, Inc. (HOLX)

crwefinancelogo2

signup3m

 

 

Gen-Probe Incorporated (NASDAQ:GPRO) recently reported financial results for the third quarter of 2010, highlighted by 19% growth in non-GAAP earnings per share (NYSEARCA:EPS) and 8% growth in product sales and total revenues.

"Gen-Probe's third quarter financial results demonstrate our ability to generate solid top- and bottom-line growth in the face of challenging business conditions," said Carl Hull, the Company's president and chief executive officer.  "In addition, the major R&D initiatives that we expect to reinvigorate product sales growth remain on track, with four US regulatory filings already complete this year and our APTIMA HPV submission anticipated in the next month."

Clinical diagnostics sales growth in the third quarter of 2010 was driven by the APTIMA Combo 2 assay for detecting Chlamydia and gonorrhea, and by Prodesse products, which were not part of Gen-Probe in the prior year period.  Compared to the prior year period, foreign exchange fluctuations reduced clinical diagnostics sales by an estimated $0.5 million, or less than 1%. 

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 27 years of expertise in nucleic acid testing (NYSE:NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,300 people.

 

**************************************

 

 

Hiru Corporation (OTCPK:HIRU) subsidiary Jiangxi Shaungshi Pharmaceutical Co., Ltd (Shaungshi AHP) launched the Jiangxi Shaungshi Biological Medicines Institute.

Shuangshi AHP is currently researching several new veterinary drugs for development within the next two years. The company launched this new institute to strengthen and speed up the research and development processes. The Institute will allow the company a better focus and concentration of its talent in bio-tech development and research. Shaungshi AHP has elected Li Rui to be director of the institute.

Hiru Corporation intends to continue its work in the development, production and marketing of both well-established and new veterinary drugs, and nutritional additives (amino acids, vitamins, trace elements, etc.) for the Chinese market.

Hiru Corporation is pleased with this development and looks forward to future growth.

Hiru Corporation, through its subsidiary, Jiangxi RongYu Pharmaceutical Group Co., Ltd., produces Chinese herbs for the naturopathic industry in China. HIRU manufactures herbal supplements containing ginseng. HIRU sells and distributes pharmaceuticals, health and beauty products, dietary and herbal supplements, and other healthcare products. HIRU manufactures approximately 120 extracts used in traditional Chinese medicine. HIRU sells its products through regional distributors, as well as directly to the hospitals, clinics, and pharmacies in China. Hiru Corporation is based in Henderson, Nevada.

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Hiru Corporation (OTCPK:HIRU)